Filing Flows › Comparisons › ISCO vs EVFM
International Stem Cell vs Evofem Biosciences: ISCO and EVFM compared
International Stem Cell is the larger company: $2.7M of revenue in its latest quarter (Q2 2026) against $2.6M for Evofem Biosciences (Q2 2026). International Stem Cell is growing faster (+9% against -45% a year earlier). International Stem Cell is more profitable, with an operating margin of -1.3% against -94.5%.
Where the money goes: ISCO and EVFM
International Stem Cell (ISCO) · Q2 2026
International Stem Cell, Q2 2026: revenue $2.7M (+9% year over year), operating margin -1.3%, net loss $71K, operating cash flow $167K. The chart follows the revenue to costs, profit and cash.
Evofem Biosciences (EVFM) · Q2 2026
Evofem Biosciences, Q2 2026: revenue $2.6M (-45% year over year), operating margin -94.5%, net loss $11.0M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
| International Stem Cell (ISCO) | Evofem Biosciences (EVFM) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $2.7M | $2.6M |
| Revenue growth, Y/Y | +9% | -45% |
| Operating margin | -1.3% | -94.5% |
| Net earnings | −$71K | −$11.0M |
| Net margin | -2.7% | -419.1% |
| Operating cash flow | $167K | −$3.1M |
| Free cash flow | $160K | — |
Where the revenue comes from
International Stem Cell
- Biomedical Market: $2.5M (94%)
- Anti Aging Skincare Market: $151K (6%)
Questions
Which is bigger, International Stem Cell or Evofem Biosciences?
International Stem Cell is the larger company: $2.7M of revenue in its latest quarter (Q2 2026) against $2.6M for Evofem Biosciences (Q2 2026).
Is International Stem Cell or Evofem Biosciences growing faster?
International Stem Cell is growing faster (+9% against -45% a year earlier).
Which is more profitable, International Stem Cell or Evofem Biosciences?
International Stem Cell is more profitable, with an operating margin of -1.3% against -94.5%.
More: International Stem Cell earnings · how International Stem Cell makes money · Evofem Biosciences earnings · how Evofem Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.